8月20日，三鑫医疗今日收盘10.46元，下跌5.42%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到23.13倍，总市值54.64亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均59.32倍，行业中值39.97倍，三鑫医疗排 名第47位。 资金流向方面，8月20日，三鑫医疗主力资金净流出6142.59万元，近5日总体呈流出状态，5日共流出 6556.40万元。 江西三鑫医疗科技股份有限公司的主营业务是医疗器械研发、制造、销售和服务。公司的主要产品是血 液净化类、给药器具类、心胸外科类、其他类。公司荣获"国家工信部智能制造优秀场景""江西省智能 制造标杆企业""江西省先进级智能工厂""5G+工业互联网"应用示范项目等荣誉，在智能制造和数字化 转型领域获权威认可。 最新一期业绩显示，2025年半年报，公司实现营业收入7.61亿元，同比10.83%；净利润1.15亿元，同比 8.35%，销售毛利率34.97%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13三鑫医疗23.1324.034.0654.64亿行业平均 59.3254.705.08121.09亿行业中值39.9 ...

8月15日，三鑫医疗今日收盘10.01元，上涨1.21%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到22.13倍，总市值52.29亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均56.58倍，行业中值39.97倍，三鑫医疗排 名第48位。 资金流向方面，8月15日，三鑫医疗主力资金净流出835.79万元，近5日总体呈流出状态，5日共流出 2621.38万元。 江西三鑫医疗科技股份有限公司的主营业务是医疗器械研发、制造、销售和服务。公司的主要产品是血 液净化类、给药器具类、心胸外科类、其他类。公司荣获"国家工信部智能制造优秀场景""江西省智能 制造标杆企业""江西省先进级智能工厂""5G+工业互联网"应用示范项目等荣誉，在智能制造和数字化 转型领域获权威认可。 最新一期业绩显示，2025年半年报，公司实现营业收入7.61亿元，同比10.83%；净利润1.15亿元，同比 8.35%，销售毛利率34.97%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13三鑫医疗22.1323.003.8852.29亿行业平均 56.5852.305.00119.53亿行业中值39.97 ...

Core Viewpoint - Sanlian Forging is recognized as a high-quality supplier of automotive forged parts and is actively expanding into the robotics sector [1] Group 1: Product Lines and Recognition - The company has established seven product lines: hub bearings, high-pressure common rail, ball joint rods, steering knuckles, fork shafts, axles, and others [1] - Sanlian Forging has gained wide recognition from international automotive parts groups such as ZF and Schaeffler in terms of production capacity, product variety, and product quality [1] Group 2: Expansion into Robotics and Aerospace - In April 2025, the company will set up a subsidiary, Wuhu Sanlian Forging Co., Ltd., focusing on a research institute for robotics and aerospace components [1] - The main products will include planetary gear reducers, screws, shaft gears, gears, and transmission gears, which are closely related to the company's forging processes [1] Group 3: Future Growth Potential - The company has deep technical reserves and has established in-depth cooperation with several global top 100 parts groups [1] - There is an expectation for the company to gradually expand from automotive parts into the robotics and aerospace sectors, indicating potential new growth points [1] - The initial coverage of the company has been rated as "Buy" [1]

8月12日，三鑫医疗今日收盘10.75元，上涨14.24%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到23.77倍，创738天以来新低，总市值56.16亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均57.51倍，行业中值41.25倍，三鑫医疗排 名第49位。 资金流向方面，8月12日，三鑫医疗主力资金净流出72.59万元，近5日总体呈流入状态，5日共流入 1490.98万元。 江西三鑫医疗科技股份有限公司的主营业务是医疗器械研发、制造、销售和服务。公司的主要产品是血 液净化类、给药器具类、心胸外科类、其他类。公司荣获"国家工信部智能制造优秀场景""江西省智能 制造标杆企业""江西省先进级智能工厂""5G+工业互联网"应用示范项目等荣誉，在智能制造和数字化 转型领域获权威认可。 最新一期业绩显示，2025年半年报，公司实现营业收入7.61亿元，同比10.83%；净利润1.15亿元，同比 8.35%，销售毛利率34.97%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13三鑫医疗23.7724.704.1756.16亿行业平均 57.5153.344.97120.28 ...

Core Viewpoint - The company reported a total revenue of 4.004 billion yuan for 2024, representing a year-on-year increase of 13.24%, while the net profit attributable to shareholders decreased by 14.28% to 780 million yuan [2][3]. Financial Performance - Total revenue for 2024 was 4,004,463,319.82 yuan, up from 3,536,132,714.02 yuan in 2023 [3]. - Net profit attributable to shareholders was 780,690,051.75 yuan, down from 910,754,003.74 yuan in the previous year [3]. - Deducting non-recurring gains and losses, the net profit was 744,252,350.90 yuan, a decrease from 867,457,631.43 yuan [3]. - The net cash flow from operating activities was 750,261,880.49 yuan, down 42.10% from 1,295,880,336.01 yuan [3]. - Basic earnings per share were 1.37 yuan, compared to 1.60 yuan in 2023 [3]. - The weighted average return on equity was 15.65%, down from 20.31% the previous year [3][30]. Dividend Distribution - The company proposed a dividend distribution plan of 5 yuan per 10 shares (including tax) for all shareholders [2]. Asset and Liability Changes - As of the end of 2024, total assets amounted to 7.201 billion yuan, an increase from 6.728 billion yuan in 2023 [3]. - Cash and cash equivalents decreased by 28.41%, while inventory increased by 34.33% [44][50]. - The company's liabilities saw an increase in accounts payable by 68.44% [47]. Research and Development - The total R&D expenditure for 2024 was 126 million yuan, a year-on-year increase of 1.8%, accounting for 3.16% of total revenue [54]. Shareholder Structure - The top ten shareholders included new entrants such as Hong Kong Central Clearing Limited and Liu Busong, replacing some previous shareholders [59].

证券代码：605089 证券简称：味知香 公告编号：2025-017 （1）按产品类别分类 单位：元 （2）按销售地区分类 单位：元 1 苏州市味知香食品股份有限公司 2024 年度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《上海证券交易所上市公司自律监管指引第 3 号行业信息披露：第十四 号—食品制造》的相关规定，现将苏州市味知香食品股份有限公司（以下简称"公 司"或"味知香"） 2024 年度主要经营数据公告披露如下： 一、报告期经营情况 2024 年度，公司实现营业收入 67,203.63 万元，较上年同期下降 15.90%。其 中，主营业务收入 66,344.09 万元，较上年同期下降 15.82%。主营业务收入构成 情况具体如下： | 产品类别 | 年度 2024 | 年度 2023 | 变动情况（%） | | --- | --- | --- | --- | | 肉禽类 | 446,561,833.68 | 530,467,171.74 | -15.82 | | 其中：牛肉类 | 2 ...